Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates

Aligos Therapeutics Inc. (NASDAQ:ALGS) shares are up during Thursday’s session following the company’s announcement of an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. China Licensing Deal Drives The agreement aims to develop and commercialize pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection in Greater China, which is expected to enhance its market position significantly. Aligos Therapeutics operates as a clinical-stage biotechnology company developing therapies for liver and viral diseases. The deal includes an upfront milestone payment of $25 million and potential additional milestones totaling up to $420 million, as well as tiered royalties on net sales, positioning Aligos for future growth in a region with over 90 million people living with HBV. This agreement is contingent upon Amoytop receiving approval at a Shareholders’ Meeting, anticipated within 30 days. The partnership is expected to extend Aligos’s cash runway into the fourth quarter of 2026, supporting its ongoing clinical trials and development efforts. Read Also: Nuclear Stocks Rise As White House Launches Space Nuclear Power Strategy Clinical Trial Progress And Safety Profile Researchers are currently evaluating pevifoscorvir sodium in the Phase 2 B-SUPREME study against the nucleoside analog tenofovir disoproxil fumarate, with the second interim analysis expected in the second half of 2026 and topline data planned for 2027. The independent Data Safety Monitoring Review Board (DSMB) recommended increasing the sample size of Part 2a from the currently enrolled 74 participants to 100 participants. Investigators performed a futility analysis; the results did not meet the prespecified futility criteria, per the statistical analysis plan. The study drugs demonstrated good tolerability, with no clinically concerning laboratory, physical examination, vital sign, or ECG abnormalities. To date, the study has not observed any viral breakthrough related to the study drugs. Technical Setup Signals Balanced Momentum Aligos Therapeutics is currently trading within a robust technical setup, positioned 13.1% above its 20-day simple moving average (SMA) and 1% above its 100-day SMA, suggesting a strong short-term trend. However, the stock is trading 2.6% below its 200-day SMA, indicating some challenges in maintaining long-term momentum. The relative strength index (RSI) is at 47.46, reflecting neutral momentum, which suggests that the stock is neither overbought nor oversold at this time. This positioning indicates a balanced state, with potential for upward movement if buying pressure increases. Key Resistance: $9.00 — This level may act as a barrier for upward price movement. Key Support: $8.50 — A critical level where buying interest could emerge. The stock has shown a strong 12-month performance with a return of 62.36%, indicating a solid upward trajectory over the past year. Currently, Aligos is trading near the middle of its 52-week range, suggesting there is room for both upward and downward movement depending on market conditions. ALGS Price Action: Aligos Therapeutics shares were up 9.70% at $8.14 at the time of publication on Thursday, according to Benzinga Pro data. Image via Shutterstock